NASDAQ · GUTS
Healthcare · Biotechnology
$0.56
Down-$0.00 (-0.44%)
Updated Sep 17, 2026, 1:22 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GUTS does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning GUTS.
GUTS research
Company profile and research snapshot.
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2026 | Craig-Hallum | Buy | — |
| Jun 4, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 24, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 26, 2026 | Canaccord Genuity | Buy | — |
| Jan 30, 2026 | Morgan Stanley | Equal-Weight | — |
Generated Sep 17, 2026, 11:18 AM
Fractyl Health's stock is down a modest 0.44% today following the company's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference. While the presentation itself appears neutral in tone, the minimal decline suggests investors are taking a measured approach to the company's strategic messaging without significant new catalysts emerging.
Bottom line: Fractyl Health's conference appearance represents a standard corporate engagement activity that has not materially moved investor sentiment in either direction. Until the company delivers concrete clinical results, commercial traction, or strategic partnerships, GUTS may continue trading sideways as investors await more meaningful catalysts to justify their positions.
SeekingAlpha · Sep 14, 2026
Fractyl Health, Inc. (GUTS) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 5:35 PM EDTCompany ParticipantsHarith Rajagopalan -...
Yahoo · Sep 9, 2026
BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Investment ConferenceFormat: On-demand
Yahoo · Sep 1, 2026
Fractyl Health (NASDAQ:GUTS) outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines. The company said Revita is designed for post-GLP-
SeekingAlpha · Sep 1, 2026
Fractyl Health, Inc. (GUTS) Discusses Commercialization Strategy for Investigational Post-GLP-1 Procedural Therapy September 1, 2026 11:00 AM EDTCompany...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GUTS.
